Dr. Koo on Degarelix for the Treatment of Prostate Cancer

Alec S. Koo, MD
Published: Tuesday, Nov 24, 2015



Alec S. Koo, MD, FACS, managing partner, Skyline Urology, board of directors, Large Urology Group Practice Association (LUGPA), discusses degarelix (Firmagon) for the treatment of patients with prostate cancer.

Degarelix is an LHRH antagonist that, both functionally and theoretically, has advantages over agonists. It also suppresses testosterone levels quicker and more efficiently, Koo explains.

Usually, when patients begin on agonists, an initial flare occurs and testosterone levels take longer to drop, Koo says. Degarelix should be administered when patients first start on LHRH therapy.
SELECTED
LANGUAGE


Alec S. Koo, MD, FACS, managing partner, Skyline Urology, board of directors, Large Urology Group Practice Association (LUGPA), discusses degarelix (Firmagon) for the treatment of patients with prostate cancer.

Degarelix is an LHRH antagonist that, both functionally and theoretically, has advantages over agonists. It also suppresses testosterone levels quicker and more efficiently, Koo explains.

Usually, when patients begin on agonists, an initial flare occurs and testosterone levels take longer to drop, Koo says. Degarelix should be administered when patients first start on LHRH therapy.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Current Perspectives on Preventing and Managing Tumor Lysis SyndromeJun 30, 20191.0
Community Practice Connections™: 2nd Annual International Congress on Oncology Pathology™Aug 31, 20191.5
Publication Bottom Border
Border Publication
x